AstraZeneca (AZN +5.7%) and AbbVie (ABBV -1.5%)
have agreed to settle their tit-for-tat patent infringement complaints
related to their respective kinase inhibitors Calquence (acalabrutinib)
and Imbruvica (ibrutinib).
AbbVie’s Pharmacyclics unit sued AZN in 2017
shortly after the FDA OK’d Calaquence for mantle cell lymphoma. AZN’s
Acerta unit retaliated with a suit of its own. Both claimed that the
other’s product infringed on certain of their patents.
Settlement terms remain confidential.
https://seekingalpha.com/news/3509214-abbvie-astrazeneca-settle-respective-patent-suits-rival-cancer-drugs
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.